Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma

BACKGROUND: In patients with metastatic renal cell cancer, based on limited evidence, increased sunitinib exposure is associated with better outcome. The survival and toxicity data of patients receiving individualized dose escalated sunitinib therapy as compared to standard management were analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales: Maráz, Anikó, Cserháti, Adrienn, Uhercsák, Gabriella, Szilágyi, Éva, Varga, Zoltán, Révész, János, Kószó, Renáta, Varga, Linda, Kahán, Zsuzsanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856318/
https://www.ncbi.nlm.nih.gov/pubmed/29544452
http://dx.doi.org/10.1186/s12885-018-4209-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856318/
https://www.ncbi.nlm.nih.gov/pubmed/29544452
http://dx.doi.org/10.1186/s12885-018-4209-9

Ejemplares similares